Chen et al. [24] found that in Chinese patients with advanced NSCLC aged 80 years or older, patients who received EGFR–TKI therapy had a significantly better prognosis (hazard ratio: 0.56), a benefit not found in chemotherapy or radiotherapy group. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.